The Importance of Trastuzumab Deruxtecan in HER2+ Breast Cancer Treatment
In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.
In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, medical oncologist, clinical research leader, and senior vice president of the clinical research division at Fred Hutchinson Cancer Center in Seattle, WA, and head of the division of hematology and oncology at the University of Washington Department of Medicine, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research.
Fam trastuzumab deruxtecan-nxki (Enhertu; T-DXd) is one of the most important targeted therapies in the space. According to Hurvitz, the drug made its introduction in 2019 as part of a phase 1, single-arm trial (DESTINY-Breast01; NCT03248492) that include heavily-pretreated patients with HER2-positive breast cancer. In the study T-DXd achieved an objective response rate (ORR) of over 60%, and a progression-free survival (PFS) of over 16 months. Hurvitz explains that at the time, oncologists had never seen such impressive results with any therapy for HER2-positive breast cancer. These data led to the accelerate approval of T-DXd.
Then, in the DESTINY-Breast03 (NCT03529110), a confirmatory trial, investigators explored T-DXd versus trastuzumab emtansine (Kadcycla; T-DM1). T-DXd demonstrated a statistically significant improvement in PFS vs T-DM1, says Hurvitz, as well as improvement in ORR, and a trend toward improvement in overall survival (OS).
In 2022, DESTINY-Breast04 (NCT03734029) findings were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and later published. In this study, T-DXd was administered to patients with HER2-low, hormone receptor–positive metastatic breast cancer (mBC) and achieved a 36% reduction in the risk of death compared with physician’s choice of chemotherapy. DESTINY-Breast04 led to the FDA approval of T-DXd for the treatment of HER2-low mBC.
In terms of ongoing research, studies of bispecific antibodies, antibody drug conjugates, and bispecific T-cell engager therapies are interesting. The unanswered questions in the field, according to Hurvitz, include how to properly treat patients with brain metastases and leptomeningeal disease as well as how to sequence available therapies.
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Wei Assesses Role of TROP2 and HER2 Status in Treatment With Sacituzumab for ER+ mBC
September 26th 2024During an in-person Community Case Forum in partnership with the Rocky Mountain Oncology Society, Mei Wei, MD, discussed data from the TROPiCS-02 trial of sacituzumab govitecan in patients with metastatic breast cancer.
Read More
